[Progress in the treatment of mild hemophilia. Liberation of factor VIII from the vascular endothelium with 1-desamino-8-D-arginine vasopressin].
Sufficient increase in plasma of factor VIII activities with a view to carrying out surgery in mild and moderate Haemophilia A and von Willebrand's disease was achieved by intravenous infusion of 1-desamino-8-D-arginine vasopressin (DDAVP). 15 patients were treated with success and three patients had to be transfused with factor VIII concentrates to control postoperative hemorrhage. DDAVP therapy makes transfusion unnecessary in selected patients. This is an important therapeutic advance as long as the use of blood products does involve danger of infecting the recipient. Another advantage is that DDAVP therapy is much cheaper than factor VIII concentrate.